March 14th 2025
"Ultimately, there is no 'right choice' when it comes to urinary diversion," writes Anne K. Schuckman, MD.
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
March 10th 2025"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.
Data refute concerns about telehealth as Congress weighs legislation
March 7th 2025“Five years after telehealth suddenly became a routine part of care for most Americans, we show that it has not led to runaway utilization or spending. This kind of in-depth analysis can inform its future," says Chad Ellimoottil, MD, MS.
Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma
February 26th 2025"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD.